Abu Dhabi, UAE– 30 October 2024- M42 has appointed Paul Jones as the Chief Executive Officer of its Omics Centre of Excellence. The Omics Centre of Excellence plays a crucial role in M42’s global efforts to drive innovation in healthcare systems and contribute to international efforts focused on disease prevention, early detection, treatment optimization and effective monitoring.

Under Paul’s leadership, the Centre will continue advancing initiatives in Abu Dhabi, collaborating with healthcare providers and other industry players to develop precision medicine solutions tailored to the unique needs of individuals in the UAE and beyond. Furthermore, Paul will spearhead the Centre’s efforts in large-scale genomics, including those related to the facilitation of the flagship Emirati Genome Program, to incorporate genomic research into national health priorities. In addition, he will champion the application of emerging technologies with the potential for population-level impact.

Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer of M42 and Chairman of Cleveland Clinic Abu Dhabi, said, “We are delighted to welcome Paul to lead our efforts at the Omics Centre of Excellence as we continue to expand our capabilities to create meaningful and positive impact.”

Also Read: M42 appoints Dr. Summia Zaher as CEO of Danat Al Emarat

Paul Jones, CEO of Omics Centre of Excellence, added, “I’m excited to be joining M42 to lead their pioneering efforts in genomics, driving innovation towards precision medicine and preventive health. Genomic data and insights will help advance personalized treatments and allow for the development of cutting-edge therapies. Weaving together clinical and research agendas, the Omics Centre of Excellence stands as one of the most technologically advanced facilities of its kind, with exceptional potential for growth and impact. Also, I look forward to collaborating with its world-class team to realize our global ambitions.”